DCGI approves DRDO-developed anti-Covid oral drug, could reduce supplemental oxygen dependence
As the COVID-19 pandemic continues to send tremors across the medical fraternity by challenging therapeutic approaches, physicians and researchers are turning to existing drugs for answers. One such drug is Ivermectin. Now, a new review study has stated that the immediate use of the drug globally can end the SARS-CoV-2-caused pandemic.
The peer-reviewed study led by the Front Line COVID-19 Critical Care Alliance (FLCCC), scrutinized published peer-reviewed studies, expert meta-analyses, manuscripts, and epidemiological studies of areas with distribution efforts of Ivermectin. It concluded that Ivermectin is an effective treatment for COVID-19 as well as efficacious prophylaxis (preventive medication).